Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease
Public ClinicalTrials.gov record NCT00492960. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During a Gluten Challenge
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study was conducted to evaluate the efficacy of multiple doses of larazotide acetate in preventing intestinal permeability changes induced by a 6- week gluten challenge in subjects with celiac disease.
Study identification
- NCT ID
- NCT00492960
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 171 participants
Conditions and interventions
Conditions
Interventions
- larazotide acetate Drug
- placebo Drug
- 900 mg gluten Dietary Supplement
Drug · Dietary Supplement
Eligibility (public fields only)
- Age range
- 18 Years to 72 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2007 (Actual)
- Primary completion
- Oct 2008 (Actual)
- Completion
- Mar 2009 (Actual)
- Last update posted
- Sep 20, 2017
2007 – 2009
United States locations
- U.S. sites
- 17
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study Site | Scottsdale | Arizona | 85259 | — |
| Study Site | Colorado Springs | Colorado | 80907 | — |
| Study Site | Chicago | Illinois | 60637 | — |
| Study Site | Lexington | Kentucky | 40536 | — |
| Study Site | Hagerstown | Maryland | 21740 | — |
| Study Site | Boston | Massachusetts | 02215 | — |
| Study Site | Troy | Michigan | 48084 | — |
| Study Site | Rochester | Minnesota | 55905 | — |
| Study Site | New York | New York | 10032 | — |
| Study Site | Asheville | North Carolina | 28801 | — |
| Study Site | Cleveland | Ohio | 44195 | — |
| Study Site | Philadelphia | Pennsylvania | 19107 | — |
| Study Site | Pittsburgh | Pennsylvania | 15243 | — |
| Study Site | Houston | Texas | 77030 | — |
| Study Site | Plano | Texas | 75093 | — |
| Study Site | Richmond | Virginia | 23298 | — |
| Study Site | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00492960, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 20, 2017 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00492960 live on ClinicalTrials.gov.